SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent ...

FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twelve systemic lupus erythematosus (SLE) patients now treated; first systemic sclerosis (SSc) patient ...

Scientists at UCLA have developed an "off-the-shelf" cell-based immunotherapy that was able to track down and kill pancreatic cancer cells even after they had spread to other organs. In a mouse study, ...

The study showed no link between load-managed players and a decreased risk of injury. Shaun Powell The NBA sent data from an exhaustive study to its teams this week that showed no link between ...

Learn how to initialize and manage EEPROM settings on Arduino to store data like user preferences, calibration values, or configuration settings — even after power off! This trick helps make your ...

Twelve people with type 1 diabetes who received an investigational off-the-shelf stem cell therapy were able to produce their own insulin and keep healthy blood glucose levels for at least one year, ...

Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. You can reach Liz on Signal at LizC.22. Twelve people with type 1 diabetes who received ...

Fate Therapeutics' off-the-shelf cell therapy product platform, including FT819, is gaining significant exposure by being selected for an oral presentation at the prominent EULAR 2025 congress. The ...

Human induced pluripotent stem cells (iPSCs) possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company’s proprietary iPSC ...

SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent ...